Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brain atrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    170 result(s) found for: Brain atrophy. Displaying page 1 of 9.
    1  2  3  4  5  6  7  8  9  Next»
    EudraCT Number: 2009-014644-11 Sponsor Protocol Number: MSA-RAS-202 Start Date*: 2009-12-08
    Sponsor Name:Teva Pharmaceutical Industries Ltd
    Full Title: A Multi-centered, Randomized, Double-blind, Placebo-controlled Clinical Trial to Assess the Efficacy, Safety, and Tolerability of Rasagiline Mesylate 1 mg in Patients with Multiple System Atrophy o...
    Medical condition: Multiple System Atrophy of the Parkinsonian Subtype
    Disease: Version SOC Term Classification Code Term Level
    12.0 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) ES (Completed) HU (Completed) AT (Completed) NL (Completed) IT (Completed) PT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003231-29 Sponsor Protocol Number: ATH434-201 Start Date*: 2022-07-26
    Sponsor Name:Alterity Therapeutics Limited
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in Multiple System Atrophy
    Medical condition: Multiple System Atrophy (MSA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) FR (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-004383-65 Sponsor Protocol Number: SRK-015-002 Start Date*: 2019-10-30
    Sponsor Name:Scholar Rock, Inc.
    Full Title: Phase 2 Active Treatment Study to Evaluate the Efficacy and Safety of SRK-015 in Patients with Later-Onset Spinal Muscular Atrophy
    Medical condition: Later Onset Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10079415 Spinal muscular atrophy type III LLT
    20.0 100000004850 10079416 Spinal muscular atrophy type II LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) ES (Ongoing) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2022-000336-28 Sponsor Protocol Number: TAK-341-2001 Start Date*: 2022-10-21
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple...
    Medical condition: Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001281-13 Sponsor Protocol Number: KS-2004-06-SET Start Date*: 2005-11-15
    Sponsor Name:DSC Services, s.r.o.
    Full Title: Observational Study of Early Interferon beta 1-a Treatment in High Risk Subjects after CIS (SET Study)
    Medical condition: Clinically isolated syndrome suspected from demyelinating event (no better explanation for present symptoms)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018157-23 Sponsor Protocol Number: D0490C00014 Start Date*: 2010-11-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Multi-Centre, Double-Blind, Randomised, Placebo-Controlled, Parallel Group 12-Month Treatment, Adaptive Design Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics ...
    Medical condition: Multiple system atrophy
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064060 Multiple system atrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) ES (Prematurely Ended) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002087-12 Sponsor Protocol Number: BN40703 Start Date*: 2018-12-07
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN-LABEL STUDY OF RISDIPLAM IN INFANTS WITH GENETICALLY DIAGNOSED AND PRESYMPTOMATIC SPINAL MUSCULAR ATROPHY
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    20.0 10010331 - Congenital, familial and genetic disorders 10079419 Spinal muscular atrophy pre-symptomatic LLT
    Population Age: Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) PL (Trial now transitioned) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-005024-37 Sponsor Protocol Number: 202100647 Start Date*: 2022-01-24
    Sponsor Name:University Medical Center Groningen
    Full Title: Evaluation of [18F]MC225 to measure P-glycoprotein function in neurodegenerative disease
    Medical condition: - Alzheimer's disease - Mild Cognitive Impairment - Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001100-38 Sponsor Protocol Number: BHV3241-301 Start Date*: 2019-12-13
    Sponsor Name:Biohaven Pharmaceuticals, Inc
    Full Title: Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy (M-STAR Study)
    Medical condition: Multiple System Atrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10064060 Multiple system atrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000506-34 Sponsor Protocol Number: EMERA006 Start Date*: 2019-02-04
    Sponsor Name:NBMI Science Ltd.
    Full Title: EMERA006- A pilot, exploratory, randomised, placebo-controlled, double blinded, cross-over, Phase 2a study to explore efficacy and safety of NBMI treatment in patients with Progressive Supranuclear...
    Medical condition: PSP or MSA
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003622-16 Sponsor Protocol Number: T214/2016 Start Date*: 2017-09-19
    Sponsor Name:Turku University Hospital
    Full Title: Targeting SPMS: Effect of teriflunomide treatment on microglial activation in an MS patient cohort at risk of progression. A [11C]PK11195 Brain PET study.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002277-22 Sponsor Protocol Number: AMYPAD-02 Start Date*: 2018-09-12
    Sponsor Name:Stichting VUmc
    Full Title: AMYPAD Prognostic and Natural History Study (PNHS), an open label, prospective, multicentre, cohort study in individuals without dementia to evaluate the additional value of quantitative amyloid im...
    Medical condition: Alzheimer's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) ES (Completed) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023023-19 Sponsor Protocol Number: CFTY720DIT01 Start Date*: 2010-12-28
    Sponsor Name:NOVARTIS FARMA
    Full Title: A 18-month, open-label, rater-blinded, randomized, multi-center, active-controlled, parallel-group pilot study to assess efficacy and safety of fingolimod (Gilenya) in comparison to interferon beta...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002614-10 Sponsor Protocol Number: 10112 Start Date*: 2005-05-17
    Sponsor Name:Lundbeck Limited
    Full Title: A 1-Year Randomised, Double-Blind Placebo-Controlled Study to Evaluate the Effects of Memantine on Rate of Brain Atrophy in Patients with Alzheimer’s Disease
    Medical condition: Probable Alzheimer's Disease of moderate severity.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002295-40 Sponsor Protocol Number: 08-06-2018-paracet Start Date*: 2018-09-11
    Sponsor Name:Copenhagen Neuromuscular Center
    Full Title: Pharmacokinetics and safety of treatment with paracetamol in children and adults with spinal muscular atrophy and cerebral palsy
    Medical condition: Spinal muscular atrophy type II (SMA II) Cerebral palsy (CP)
    Disease:
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001836-69 Sponsor Protocol Number: Vort-MCI_001 Start Date*: 2021-09-17
    Sponsor Name:Medical University of Vienna
    Full Title: Effects of Vortioxetine in Mild Cognitive Impairment measured by Functional Magnetic Resonance Imaging
    Medical condition: Mild cognitive impairment
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003127-38 Sponsor Protocol Number: NL71001.029.19 Start Date*: 2020-04-09
    Sponsor Name:VUmc Neurology Department
    Full Title: Efficacy of add-on high dose simvastatin on markers for disease progression in MS patients treated with ocrelizumab and natalizumab (SIMSON), a phase II clinical trial.
    Medical condition: Multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-005112-42 Sponsor Protocol Number: C14-62 Start Date*: 2015-06-22
    Sponsor Name:INSERM
    Full Title: A comparative phase2 study assessing the efficacy of triheptanoin, an anaplerotic therapy in Huntington's Disease (TRIHEP 3)
    Medical condition: Huntington's disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2008-005213-22 Sponsor Protocol Number: SUPREMES-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Charite Universitätsmedizin Berlin
    Full Title: SUPREMES - Sunphenon in progressive forms of multiple sclerosis
    Medical condition: primary and secondary progressive forms of multiple sclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024477-39 Sponsor Protocol Number: 105MS302 Start Date*: 2011-05-06
    Sponsor Name:Biogen Idec Limited
    Full Title: A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis
    Medical condition: Relapsing Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029205 - Nervous system disorders 10048393 Multiple sclerosis relapse PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) DE (Completed) ES (Completed) BG (Completed) EE (Completed) GB (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 12 02:30:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA